The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases
Open accessAbstract
Monoclonal antibodies are being developed as therapeutics to complement drugs and vaccines or to fill the gap where no drugs or vaccines exist. These therapeutic antibodies (ThAb) may be especially important for infectious diseases in which there is antibiotic resistance, toxin-mediated pathogenesis, or for emerging pathogens. The unique structure of antibodies determines the specific nature of the effector function, so when developing ThAb, the desired effector functions need to be considered and integrated into the design and development processes to ensure maximum efficacy and safety. Antibody subclass is a critical consideration, but it is noteworthy that almost all ThAb that are licenced or currently in development utilise an IgG1 backbone. This review outlines the major structural properties that vary across subclasses, how these properties affect functional immunity, and discusses the various approaches used to study subclass responses to infectious diseases. We also review the factors associated with the selection of antibody subclasses when designing ThAb and highlight circumstances where different subclass properties might be beneficial when applied to particular infectious diseases. These approaches are critical to the future design of ThAb and to the study of naturally-acquired and vaccine-induced immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Of Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822 · cited 1×
“…observed differences in subclass specific function obtained in animal models cannot be 178 V. Irani et al. / Molecular Immunology 67 (2015) 171–182 d p a I ( d s d 4 t s i u a s t 2 t m 4 c i t v i g i f 1 ( t s t c P 1 t h a i m 1 1 a 1 irectly inferred for humans (Mestas and Hughes, 2004).”
BackgroundSequences of proteins of immunological interest
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90805-4 · Cited by 3,363
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Fc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901
Anatomy of the antibody molecule
Padlan, E. A. (1994) · Molecular Immunology · doi:10.1016/0161-5890(94)90001-9 · Cited by 896
Properties of mouse and human IgG receptors and their contribution to disease models
Bruhns, P. (2012) · Blood · doi:10.1182/blood-2012-01-380121 · Cited by 847
Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
Schwab, I., & Nimmerjahn, F. (2013) · Nature Reviews Immunology · doi:10.1038/nri3401 · Cited by 820
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Diebolder, C. A., Beurskens, F. J., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J. R., et al. (2014) · Science · doi:10.1126/science.1248943 · Cited by 796
Placental transport of immunoglobulin G
Simister, N. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00334-7 · Cited by 783
Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770
DiLillo, D. J., Tan, G. S., Palese, P., & Ravetch, J. V. (2014) · Nature Medicine · doi:10.1038/nm.3443 · Cited by 749 · cited 2×
“…a result of interaction with FcRn, improved effector unction via engagement with a range of Fc receptors, and in some ases, more effective neutralisation when compared to the coresponding Fab fragment (Abboud et al., 2010; Bournazos et al., 014; DiLillo et al., 2014; Halper-Stromberg et al., 2014).”
BackgroundThe 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex
Sondermann, P., Huber, R., Oosthuizen, V., & Jacob, U. (2000) · Nature · doi:10.1038/35018508 · Cited by 719
Krapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674
The function of Fcγ receptors in dendritic cells and macrophages
Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., & Lambrecht, B. N. (2014) · Nature Reviews Immunology · doi:10.1038/nri3582 · Cited by 639
Brüggemann, M., Williams, G. T., Bindon, C. I., Clark, M. R., Walker, M. R., Jefferis, R., Waldmann, H., & Neuberger, M. S. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.5.1351 · Cited by 607
Passive antibody therapy for infectious diseases
Casadevall, A., Dadachova, E., & Pirofski, L.-A. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro974 · Cited by 531
Type I and type II Fc receptors regulate innate and adaptive immunity
Pincetic, A., Bournazos, S., DiLillo, D. J., Maamary, J., Wang, T. T., Dahan, R., Fiebiger, B.-M., & Ravetch, J. V. (2014) · Nature Immunology · doi:10.1038/ni.2939 · Cited by 514
Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
Bournazos, S., Klein, F., Pietzsch, J., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2014) · Cell · doi:10.1016/j.cell.2014.08.023 · Cited by 493
Liu, H., & May, K. (2012) · mAbs · doi:10.4161/mabs.4.1.18347 · Cited by 484
Introduction to current and future protein therapeutics: A protein engineering perspective
Carter, P. J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.02.013 · Cited by 467
Crystal structure of the complex of rat neonatal Fc receptor with Fc
Burmeister, W. P., Huber, A. H., & Bjorkman, P. J. (1994) · Nature · doi:10.1038/372379a0 · Cited by 431
Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424
Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex
Martin, W. L., West, A. P., Gan, L., & Bjorkman, P. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00230-1 · Cited by 391
Halper-Stromberg, A., Lu, C.-L., Klein, F., Horwitz, J. A., Bournazos, S., Nogueira, L., Eisenreich, T. R., Liu, C., Gazumyan, A., Schaefer, U., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.043 · Cited by 381
Crystal structure of the complex of rat neonatal Fc receptor with Fc
(1995) · Trends in Genetics · doi:10.1016/0168-9525(95)90005-5 · Cited by 381
Gaboriaud, C., Juanhuix, J., Gruez, A., Lacroix, M., Darnault, C., Pignol, D., Verger, D., Fontecilla-Camps, J. C., & Arlaud, G. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307764200 · Cited by 362
Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity
Ackerman, M. E., Crispin, M., Yu, X., Baruah, K., Boesch, A. W., Harvey, D. J., Dugast, A.-S., Heizen, E. L., Ercan, A., Choi, I., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65708 · Cited by 358
The Structure of a Human Type III Fcγ Receptor in Complex with Fc
Radaev, S., Motyka, S., Fridman, W.-H., Sautes-Fridman, C., & Sun, P. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100350200 · Cited by 354
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
Hogarth, P. M., & Pietersz, G. A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2909 · Cited by 348
Analysis of immunoglobulin glycosylation by LC‐ESI‐MS of glycopeptides and oligosaccharides
Stadlmann, J., Pabst, M., Kolarich, D., Kunert, R., & Altmann, F. (2008) · PROTEOMICS · doi:10.1002/pmic.200700968 · Cited by 328
Age-related galactosylation of the N-linked oligosaccharides of human serum IgG.
Parekh, R., Roitt, I., Isenberg, D., Dwek, R., & Rademacher, T. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.5.1731 · Cited by 302
Antibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
Engineered Antibodies with Increased Activity to Recruit Complement
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291
Stapleton, N. M., Andersen, J. T., Stemerding, A. M., Bjarnarson, S. P., Verheul, R. C., Gerritsen, J., Zhao, Y., Kleijer, M., Sandlie, I., de Haas, M., et al. (2011) · Nature Communications · doi:10.1038/ncomms1608 · Cited by 286
Stavenhagen, J. B., Gorlatov, S., Tuaillon, N., Rankin, C. T., Li, H., Burke, S., Huang, L., Johnson, S., Bonvini, E., & Koenig, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0696 · Cited by 284
Adverse Effects of Human Immunoglobulin Therapy
Stiehm, E. R. (2013) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2013.05.004 · Cited by 283
The Role of Antibody Concentration and Avidity in Antiviral Protection
Bachmann, M. F., Kalinke, U., Althage, A., Freer, G., Burkhart, C., Roost, H.-P., Aguet, M., Hengartner, H., & Zinkernagel, R. M. (1997) · Science · doi:10.1126/science.276.5321.2024 · Cited by 267
Selective IgG subclass deficiency: quantification and clinical relevance
JEFFERIS, R., & KUMARARATNE, D. S. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb05339.x · Cited by 265
Bondt, A., Rombouts, Y., Selman, M. H. J., Hensbergen, P. J., Reiding, K. R., Hazes, J. M. W., Dolhain, R. J. E. M., & Wuhrer, M. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.039537 · Cited by 264
Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum
Wuhrer, M., Stam, J. C., van de Geijn, F. E., Koeleman, C. A. M., Verrips, C. T., Dolhain, R. J. E. M., Hokke, C. H., & Deelder, A. M. (2007) · PROTEOMICS · doi:10.1002/pmic.200700289 · Cited by 263
Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms
Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259
West, A. P., & Bjorkman, P. J. (2000) · Biochemistry · doi:10.1021/bi000749m · Cited by 257
Flexibility of human IgG subclasses
Roux, K. H., Strelets, L., & Michaelsen, T. E. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.7.3372 · Cited by 254
Isotype and glycoform selection for antibody therapeutics
Jefferis, R. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.021 · Cited by 252
Stanisic, D. I., Richards, J. S., McCallum, F. J., Michon, P., King, C. L., Schoepflin, S., Gilson, P. R., Murphy, V. J., Anders, R. F., Mueller, I., et al. (2009) · Infection and Immunity · doi:10.1128/iai.01129-08 · Cited by 249
Self-citationStructure and activation of the C1 complex of complement: unraveling the puzzle
Gaboriaud, C., Thielens, N. M., Gregory, L. A., Rossi, V., Fontecilla-Camps, J. C., & Arlaud, G. J. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.04.008 · Cited by 247
Human immunoglobulin allotypes: Possible implications for immunogenicity
Jefferis, R., & Lefranc, M.-P. (2009) · mAbs · doi:10.4161/mabs.1.4.9122 · Cited by 235
Structural characterization of a human Fc fragment engineered for lack of effector functions
Oganesyan, V., Gao, C., Shirinian, L., Wu, H., & Dall'Acqua, W. F. (2008) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444908007877 · Cited by 197
Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities
Armour, K. L., Clark, M. R., Hadley, A. G., & Williamson, L. M. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j · Cited by 192
Richards, J. S., Stanisic, D. I., Fowkes, F. J. I., Tavul, L., Dabod, E., Thompson, J. K., Kumar, S., Chitnis, C. E., Narum, D. L., Michon, P., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/656413 · Cited by 192
Self-citationAbnormal glycosylation of serum igg from patients with chronic inflammatory diseases
Tomana, M., Schrohenloher, R. E., Koopman, W. J., Alarcän, G. S., & Paul, W. A. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310304 · Cited by 177
Chapter 4 Multitasking by Exploitation of Intracellular Transport Functions
Ward, E. S., & Ober, R. J. (2009) · Advances in immunology · doi:10.1016/s0065-2776(09)03004-1 · Cited by 176
Ambrosino, D. M., Schiffman, G., Gotschlich, E. C., Schur, P. H., Rosenberg, G. A., DeLange, G. G., van Loghem, E., & Siber, G. R. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111909 · Cited by 175
Lu, J., Chu, J., Zou, Z., Hamacher, N. B., Rixon, M. W., & Sun, P. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418812112 · Cited by 173
Vafa, O., Gilliland, G. L., Brezski, R. J., Strake, B., Wilkinson, T., Lacy, E. R., Scallon, B. J., Teplyakov, A., Malia, T., & Strohl, W. R. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.035 · Cited by 168
Schlesinger, J. J., Foltzer, M. A., & Chapman, S. (1993) · Virology · doi:10.1006/viro.1993.1015 · Cited by 163
Ramsland, P. A., Farrugia, W., Bradford, T. M., Sardjono, C. T., Esparon, S., Trist, H. M., Powell, M. S., Tan, P. S., Cendron, A. C., Wines, B. D., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101467 · Cited by 163
Self-citationEarly immune responses accompanying human asymptomatic Ebola infections
Leroy, E. M., Baize, S., Debré, P., Lansoud-Soukate, J., & Mavoungou, E. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01517.x · Cited by 157
T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice
Yuan, R., Casadevall, A., Oh, J. S., & Scharff, M. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2483 · Cited by 153
Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum
Yamada, E., Tsukamoto, Y., Sasaki, R., Yagyu, K., & Takahashi, N. (1997) · Glycoconjugate Journal · doi:10.1023/a:1018582930906 · Cited by 151
Sanford, J., Lupan, D. M., Schlageter, A. M., & Kozel, T. R. (1990) · Infection and Immunity · doi:10.1128/iai.58.6.1919-1923.1990 · Cited by 145
Lefranc, M., & Lefranc, G. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-842-9_34 · Cited by 143
Changes in Antigen-specific IgG1 Fc N-glycosylation Upon Influenza and Tetanus Vaccination
Selman, M. H. J., de Jong, S. E., Soonawala, D., Kroon, F. P., Adégnika, A. A., Deelder, A. M., Hokke, C. H., Yazdanbakhsh, M., & Wuhrer, M. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014563 · Cited by 142
Yuan, R., Casadevall, A., Spira, G., & Scharff, M. D. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.4.1810 · Cited by 141
Mehlhop, E., Ansarah-Sobrinho, C., Johnson, S., Engle, M. J., Fremont, D. H., Pierson, T. C., & Diamond, M. (2007) · Cell Host & Microbe · doi:10.1016/j.chom.2007.09.015 · Cited by 141
Molecular basis of IgG subclass deficiency
Pan‐Hammarström, Q., & Hammarström, L. L. G. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.17815.x · Cited by 123
Kelly‐Quintos, C., Cavacini, L. A., Posner, M. R., Goldmann, D. A., & Pier, G. B. (2006) · Infection and Immunity · doi:10.1128/iai.74.5.2742-2750.2006 · Cited by 121
Immunoglobulin G subclass deficiency: Fact or fancy?
Buckley, R. H. (2002) · Current Allergy and Asthma Reports · doi:10.1007/s11882-002-0067-1 · Cited by 116
Therapeutic antibody engineering by high efficiency cell screening
Doerner, A., Rhiel, L., Zielonka, S., & Kolmar, H. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.11.025 · Cited by 116
A requirement for FcγR in antibody-mediated bacterial toxin neutralization
Abboud, N., Chow, S.-K., Saylor, C., Markmann, A. J., Ravetch, J. V., Scharff, M. D., & Casadevall, A. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100995 · Cited by 109
Structural changes in the oligosaccharide moiety of human IgG with aging
Shikata, K., Yasuda, T., Takeuchi, F., Konishi, T., Nakata, M., & Mizuochi, T. (1998) · Glycoconjugate Journal · doi:10.1023/a:1006936431276 · Cited by 106
IgG2m4, an engineered antibody isotype with reduced Fc function
An, Z., Forrest, G., Moore, R., Cukan, M. C., Haytko, P., Huang, L., Vitelli, S., Zhao, J. Z., Lü, P., Hua, J., et al. (2009) · mAbs · doi:10.4161/mabs.1.6.10185 · Cited by 104
FcRn: From Molecular Interactions to Regulation of IgG Pharmacokinetics and Functions
Challa, D. K., Velmurugan, R., Ober, R. J., & Ward, E. S. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_12 · Cited by 102
Cooper, L. J. N., Shikhman, A. R., Glass, D. D., Kangisser, D., Cunningham, M. W., & Greenspan, N. S. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.6.2231 · Cited by 99
Scharf, O., Golding, H., King, L. R., Eller, N. L., Frazier, D., Golding, B., & Scott, D. E. (2001) · Journal of Virology · doi:10.1128/jvi.75.14.6558-6565.2001 · Cited by 96
Yuan, R. R., Spira, G., Oh, J. S., Paizi, M., Casadevall, A., & Scharff, M. D. (1998) · Infection and Immunity · doi:10.1128/iai.66.3.1057-1062.1998 · Cited by 92
Magdelaine–Beuzelin, C., Vermeire, S., Goodall, M. D., Baert, F., Noman, M., Assche, G. V., Ohresser, M. C. P., Degenne, D., Dugoujon, J., Jefferis, R., et al. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832a06bf · Cited by 88
Shapiro, S., Beenhouwer, D. O., Feldmesser, M., Taborda, C. P., Carroll, M. C., Casadevall, A., & Scharff, M. D. (2002) · Infection and Immunity · doi:10.1128/iai.70.5.2598-2604.2002 · Cited by 84
Schlageter, A. M., & Kozel, T. R. (1990) · Infection and Immunity · doi:10.1128/iai.58.6.1914-1918.1990 · Cited by 83
Liu, Z., Gunasekaran, K., Wang, W., Razinkov, V. I., Sekirov, L., Leng, E. C., Sweet, H., Foltz, I. N., Howard, M., Rousseau, A.-M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.513366 · Cited by 83
Tian, X., Langkilde, A. E., Thórólfsson, M., Rasmussen, H. B., & Vestergaard, B. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23964 · Cited by 79
Use of Intravenous Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases
Hemming, V. G. (2001) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.8.5.859-863.2001 · Cited by 77
Anti-bacterial monoclonal antibodies: Back to the future?
Oleksiewicz, M. B., Nagy, G., & Nagy, E. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.06.001 · Cited by 75
Armour, K. L., van de Winkel, J. G. J., Williamson, L. M., & Clark, M. (2003) · Molecular Immunology · doi:10.1016/j.molimm.2003.08.004 · Cited by 74
Regulation of Immune Responses by the Neonatal Fc Receptor and Its Therapeutic Implications
Räth, T., Baker, K., Pyzik, M., & Blumberg, R. S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00664 · Cited by 71
Bartelds, G. M., de Groot, E. R., Nurmohamed, M. T., Hart, M. H. L., van Eede, P. H., Wijbrandts, C. A., Crusius, J. B. A., Dijkmans, B. A. C., Tak, P. P., Aarden, L. A., et al. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3208 · Cited by 71
Optimizing Therapeutic Antibody Function: Progress with Fc Domain Engineering
Kaneko, E., & Niwa, R. (2010) · BioDrugs · doi:10.2165/11537830-000000000-00000 · Cited by 69
Schlesinger, J. J., & Chapman, S. (1995) · Journal of General Virology · doi:10.1099/0022-1317-76-1-217 · Cited by 65
Anti-infective monoclonal antibodies: perils and promise of development
Reichert, J. M., & Dewitz, M. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1987 · Cited by 58
Cao, R., Dong, D., Liu, R.-J., Han, J., Wang, G., Zhao, H. J., Li, X., Deng, Y., Zhu, S.-Y., Wang, X., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064024 · Cited by 55
The influence of the hinge region length in binding of human IgG to human Fcγ receptors
Redpath, S., Michaelsen, T. E., Sandlie, I., & Clark, M. (1998) · Human Immunology · doi:10.1016/s0198-8859(98)00075-5 · Cited by 48
Ramsland, P. A., & Farrugia, W. (2002) · Journal of Molecular Recognition · doi:10.1002/jmr.585 · Cited by 45
Self-citationBoctor, F. N., & Peter, J. B. (1990) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb05492.x · Cited by 45
Brown, M. J., Kowalski, R., Zorman, J. K., Wang, X.-M., Towne, V., Zhao, Q., Secore, S., Finnefrock, A. C., Ebert, T., Pancari, G., et al. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00085-09 · Cited by 45
Polyclonal and Monoclonal Antibodies in Clinic
Wootla, B., Đenić, A., & Rodriguez, M. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-586-6_5 · Cited by 44
Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions
Kinder, M., Greenplate, A. R., Grugan, K. D., Soring, K. L., Heeringa, K., McCarthy, S. G., Bannish, G., Perpetua, M., Lynch, F., Jordan, R. E., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.486142 · Cited by 44
Binding and Neutralization Activity of Human IgG1 and IgG3 from Serum of HIV-Infected Individuals
Cavacini, L. A., Kuhrt, D. M., Duval, M., et al. (2003) · AIDS Research and Human Retroviruses · doi:10.1089/088922203769232584 · Cited by 41
Engineered Fc based antibody domains and fragments as novel scaffolds
Ying, T., Gong, R., Ju, T. W., Prabakaran, P., & Dimitrov, D. S. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.04.018 · Cited by 40
Vestrheim, A., Moen, A. R., Egge-Jacobsen, W. M., Reubsaet, L., Halvorsen, T. G., Bratlie, D. B., Paulsen, B. S., & Michaelsen, T. E. (2014) · Immunity Inflammation and Disease · doi:10.1002/iid3.22 · Cited by 39
On the Perplexingly Low Rate of Transport of IgG2 across the Human Placenta
Einarsdottir, H. K., Stapleton, N. M., Scherjon, S., Andersen, J. T., Rispens, T., van der Schoot, C. E., & Vidarsson, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108319 · Cited by 38
Hovenden, M., Hubbard, M., AuCoin, D. P., Thorkildson, P., Reed, D. E., Welch, W. H., Lyons, C. R., Lovchik, J. A., & Kozel, T. R. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003306 · Cited by 36
Varshney, A. K., Wang, X., Aguilar, J. L., Scharff, M. D., & Fries, B. C. (2014) · mBio · doi:10.1128/mbio.01007-14 · Cited by 36
Lazarou, M., Guevara-Patino, J. A., Jennings, R. M., McIntosh, R. S., Shi, J., Howell, S. A., Cullen, E., Jones, T., Adame-Gallegos, J. R., Chappel, J. A., et al. (2009) · Infection and Immunity · doi:10.1128/iai.00167-09 · Cited by 34
Pollack, M., Koles, N., Preston, M. J., et al. (1995) · Infection and Immunity · doi:10.1128/iai.63.11.4481-4488.1995 · Cited by 32
Miranda, L. R., Duval, M., Doherty, H., Seaman, M. S., Posner, M. R., & Cavacini, L. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.7132 · Cited by 32
Cavacini, L. A., Emes, C. L., Power, J., et al. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.7.3638 · Cited by 31
The forgotten tale of immunoglobulin allotypes in cancer risk and treatment
Pandey, J. P., & Li, Z. (2013) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-2-6 · Cited by 31
Monoclonal antibodies for prophylaxis and therapy of infectious diseases
ter Meulen, J. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.4.525 · Cited by 30
Therapeutic antibodies as a treatment option for dengue fever
Chan, K. R., Ong, E. Z., & Ooi, E. E. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.839941 · Cited by 30
Meyts, I., Bossuyt, X., Proesmans, M., & De, B. (2006) · Pediatric Allergy and Immunology · doi:10.1111/j.1399-3038.2006.00454.x · Cited by 29
Heterogeneity of IgG Glycosylation in Adult Periodontal Disease
Novak, J., Tomana, M., Shah, G. R., Brown, R., & Mestecky, J. (2005) · Journal of Dental Research · doi:10.1177/154405910508401005 · Cited by 29
Liu, F., Lopez‐Bergami, P., Duval, M., Kuhrt, D. M., Posner, M. R., & Cavacini, L. A. (2003) · AIDS Research and Human Retroviruses · doi:10.1089/088922203322230969 · Cited by 28
Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs
Mimoto, F., Kadono, S., Katada, H., Igawa, T., Kamikawa, T., & Hattori, K. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.11.017 · Cited by 26
Passive immunization: the forgotten arm of immunologically based strategies for disease containment
Gonik, B. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.06.076 · Cited by 17
Young, M. K., & Cripps, A. W. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25311 · Cited by 16 · cited 3×
“Disease specific products are sometimes enriched by pooling antibodies from individuals with high titres to these disease antigens (Young and Cripps, 2013).”
BackgroundA Conserved Host and Pathogen Recognition Site on Immunoglobulins: Structural and Functional Aspects
Wines, B. D., Trist, H. M., Farrugia, W., Ngo, C., Trowsdale, J., Areschoug, T., Lindahl, G., Fraser, J. D., & Ramsland, P. A. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0106-3_6 · Cited by 15
Self-citationGeneral Characteristics of Immunoglobulin Molecules
Nezlin, R. S. (1998) · Elsevier eBooks · doi:10.1016/b978-012517970-6/50001-1 · Cited by 15
Longitudinal Analysis of Serological Responses of Adults toHelicobacter pyloriAntigens
Perez‐Perez, G. I., Maw, A., Feingold‐Link, L., Gunn, J., Bowers, A. L., Miñano, C., Rautelin, H. I. K., Kosunen, T. U., & Blaser, M. J. (2010) · The Journal of Infectious Diseases · doi:10.1086/655660 · Cited by 12
Therapeutic antibodies and infectious diseases, Tours, France, November 20−22, 2012
Désoubeaux, G., Daguet, A., & Watier, H. (2013) · mAbs · doi:10.4161/mabs.25300 · Cited by 11
Role of passive immunotherapies in managing infectious outbreaks
Gust, A. O. I. (2012) · Biologicals · doi:10.1016/j.biologicals.2012.01.001 · Cited by 10
Association of HCMV specific IgG subclass antibody levels with gender and age
Simon, B., Kundi, M., & Puchhammer‐Stöckl, E. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.02.011 · Cited by 9
Gouilleux‐Gruart, V., SCHLEINITZ, N., & Fischer, A. (2013) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/01.all.0000433133.93564.c7 · Cited by 9
Migot‐Nabias, F., Lokossou, A. G., Vigan-Womas, I., Guitard, E., Guillotte-Blisnick, M., Noukpo, J. M., Mercereau‐Puijalon, O., Dugoujon, J., & Garcia, A. (2011) · Microbes and Infection · doi:10.1016/j.micinf.2011.04.001 · Cited by 7
Molecular Engineering III: Fc Engineering
Peipp, M., Beyer, T. D., Dechant, M., & Valerius, T. (2007) · Wiley eBooks · doi:10.1002/9783527619740.ch8 · Cited by 6
Cited by
Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188
Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies
Marques, A. C., Costa, P. J., Velho, S., & Amaral, M. H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.035 · Cited by 349
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E., & de Groot, D. J. A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.006 · Cited by 292
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
VIVID: A Web Application for Variant Interpretation and Visualization in Multi-dimensional Analyses
Tichkule, S., Myung, Y., Naung, M. T., Ansell, B. R. E., Guy, A. J., Srivastava, N., Mehra, S., Cacciò, S. M., Mueller, I., Barry, A. E., et al. (2022) · Molecular Biology and Evolution · doi:10.1093/molbev/msac196 · Cited by 11
Self-citation
Metadata
- Authors
- Irani, V., Guy, A. J., Andrew, D., Beeson, J. G., Ramsland, P. A., & Richards, J. S.
- Venue
- Molecular Immunology
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 67
- Issue
- 2
- Pages
- 171-182
- ISSN
- 0161-5890 (ISSN-L)
- OpenAlex
- W2023024432
- Cited by
- 288
- References
- 132
- FWCI
- 22.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.